Enrollment Criteria for Clinical Trials in Acute Myeloid Leukemia
- 28 February 2009
- journal article
- review article
- Published by Elsevier BV in Clinical Leukemia
- Vol. 3 (1), 14-19
- https://doi.org/10.3816/clk.2009.n.002
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AMLBlood, 2008
- Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal KaryotypeThe New England Journal of Medicine, 2005
- All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolBlood, 2002
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood, 2002
- FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemiaBlood, 2001
- A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic LeukemiaBlood, 1999
- The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 TrialBlood, 1998
- Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 GroupBlood, 1993
- The unique aspects of acute promyelocytic leukemia.Journal of Clinical Oncology, 1990
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976